https://www.chemical.ai/blog daily 0.75 2026-02-10 https://www.chemical.ai/blog/exploring-synthetic-pathways-for-deep-blue-oled-emitters-using-chemairs monthly 0.5 2026-02-10 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2e488c3e-6898-4cb5-be91-0f0e9f0b8ad1/Screenshot+2026-02-09+at+11.23.08%E2%80%AFPM.png Blog - Exploring Synthetic Pathways for Deep-Blue OLED Emitters Using ChemAIRS - Make it stand out Figure 1. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1cffbd3b-5e54-41bd-829a-f67266779fdd/Screenshot+2026-02-02+at+13.26.58.png Blog - Exploring Synthetic Pathways for Deep-Blue OLED Emitters Using ChemAIRS - Make it stand out Route 1. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/d1872e78-b25d-449d-b3d0-1b43a5f5f62d/Screenshot+2026-02-02+at+13.27.09.png Blog - Exploring Synthetic Pathways for Deep-Blue OLED Emitters Using ChemAIRS - Make it stand out Route 2. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/23ac0450-9261-40b9-8e2d-98f7374508ce/Screenshot+2026-02-02+at+13.27.18.png Blog - Exploring Synthetic Pathways for Deep-Blue OLED Emitters Using ChemAIRS - Make it stand out Route 3. https://www.chemical.ai/blog/cortevas-new-insecticide-receives-iso-name-a-new-member-joins-the-agrochemical-industry monthly 0.5 2026-01-15 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8917714b-8746-4915-9c36-259274161c1a/Screenshot+2026-01-14+at+20.49.06.png Blog - Corteva’s New Insecticide Receives ISO Name: A New Member Joins the Agrochemical Industry - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/be750243-8bf1-47af-bb42-6a37d467e75c/Screenshot+2026-01-14+at+20.52.34.png Blog - Corteva’s New Insecticide Receives ISO Name: A New Member Joins the Agrochemical Industry - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1a3ef045-7b00-4e07-9f7a-8e0e8ffaa693/Screenshot+2026-01-14+at+20.55.09.png Blog - Corteva’s New Insecticide Receives ISO Name: A New Member Joins the Agrochemical Industry - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b58cf778-d0bc-42f1-8247-a2cacb540d0f/Screenshot+2026-01-14+at+20.57.10.png Blog - Corteva’s New Insecticide Receives ISO Name: A New Member Joins the Agrochemical Industry - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.chemical.ai/blog/empowering-radical-cross-coupling-chemistry-through-ai-driven-retrosynthesis-and-real-world-validation monthly 0.5 2025-12-02 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f0768d4b-c7e9-47f4-82c5-17c21c3d0d43/Screenshot+2025-11-26+at+11.23.20.png Blog - Empowering Radical Cross-Coupling Chemistry through AI-Driven Retrosynthesis and Real-World Validation. - Make it stand out Figure 1. Conventional Polar Cross-Coupling versus Radical Cross-Coupling Approaches https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/446385ba-cb95-48c4-8b9f-c855e6e8586c/Screenshot+2025-11-30+at+15.26.56.png Blog - Empowering Radical Cross-Coupling Chemistry through AI-Driven Retrosynthesis and Real-World Validation. - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7542ff32-1482-4852-910e-65dfcf0617a6/Screenshot+2025-11-30+at+15.28.25.png Blog - Empowering Radical Cross-Coupling Chemistry through AI-Driven Retrosynthesis and Real-World Validation. - Make it stand out Figure 2. Case study 1: Canonical cross-coupling https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6405c869-e1f3-470f-83d3-430570d5e087/Screenshot+2025-11-30+at+16.00.28.png Blog - Empowering Radical Cross-Coupling Chemistry through AI-Driven Retrosynthesis and Real-World Validation. - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/203ecc4f-7059-4449-a1d5-5079f51199ca/Screenshot+2025-11-30+at+16.02.56.png Blog - Empowering Radical Cross-Coupling Chemistry through AI-Driven Retrosynthesis and Real-World Validation. - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/acc53937-649d-42a8-ad41-2b7ba8ee2b80/Screenshot+2025-11-30+at+16.04.01.png Blog - Empowering Radical Cross-Coupling Chemistry through AI-Driven Retrosynthesis and Real-World Validation. - Make it stand out Figure 4. RCC Exploration Without Precedent https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7d12aa6d-d9d3-4c64-87c2-b8bd1708c264/Screenshot+2025-11-30+at+16.06.30.png Blog - Empowering Radical Cross-Coupling Chemistry through AI-Driven Retrosynthesis and Real-World Validation. - Make it stand out Figure 5. Three ways to drive RCC. https://www.chemical.ai/blog/dl7xc1h1477b1hp21ajpef87z13c73 monthly 0.5 2025-10-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/749baa52-a83f-4467-ab97-a4cd5ebabc00/Screenshot+2025-10-14+at+23.41.48.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 1. Crystal Structure of BCL-2 with venetoclax (PDB: 6O0K). Chemical structure of Surzetoclax (ABBV-453), a next-generation BCL-2 inhibitor https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b8b1deea-a640-4d7c-8241-d4d58a51521f/Screenshot+2025-10-14+at+23.48.33.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 2. Chemical structures of commonly used BCL-2 inhibitors. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1ff90b87-d379-4888-bb85-3a22e4cf2f25/Screenshot+2025-10-14+at+23.54.34.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 3. Surzetoclax’s structure: key elements https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0ec0a442-98a9-4764-be7d-12270420f21d/Screenshot+2025-10-14+at+23.58.13.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 4. Building the 6,11,6-Fused Tricycle https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0e663afd-c5d3-4590-a1dc-82f25b5b4567/Screenshot+2025-10-15+at+00.00.49.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 5. Assembly of the Tetrahydropyran Fragment https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4f183220-e9d0-40a8-ba36-4a896227305b/Screenshot+2025-10-15+at+00.03.33.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 6. Constructing the 5,6,7-Fused Heteroaromatic System and Final Coupling https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f8070952-10ce-4134-b461-d2eecd0c2840/Screenshot+2025-10-15+at+00.07.21.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 7. Human-directed synthesis of ABBV-453 in ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a1a12152-f90c-418e-bbca-9d35c03beb4c/Screenshot+2025-10-15+at+00.09.59.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 8. Fragment 25a – The Core Tricycle https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e471c6ee-5487-4e8b-89dd-08daccb1e40a/Screenshot+2025-10-15+at+00.13.01.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 9. Fragment 12a – The THP Motif https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8ec14627-14ee-4469-a56d-0648e54c44dc/Screenshot+2025-10-15+at+00.15.17.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 10. Fragment 12b – The Azaindole-Oxazepane Tricycle https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f8b9d8c8-969d-4777-9d5a-3757d64f6e4f/Screenshot+2025-10-15+at+00.17.07.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Figure 11. Final Assembly https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/5a76c361-010b-4fc5-8b19-692a1e122809/Screenshot+2025-10-15+at+00.19.35.png Blog - Integrating Human Insight with AI: Retrosynthetic Exploration of Surzetoclax (ABBV-453) - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.chemical.ai/blog/advantages-and-challenges-of-cross-coupling-reactions-and-recent-progress-in-suzukimiyaura-reactions monthly 0.5 2025-09-24 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/9706cbe4-cd01-4e6f-86be-cd255ccacd5c/Screenshot+2025-09-22+at+14.40.49.png Blog - Advantages and Challenges of Cross-Coupling Reactions and Recent Progress in Suzuki–Miyaura Reactions - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6e687809-990e-4e74-aa0e-a1ea3df2af13/10.1021-acs.jmedchem.5c00485Figure1.pptx+%28800+x+600+px%29+%281%29.png Blog - Advantages and Challenges of Cross-Coupling Reactions and Recent Progress in Suzuki–Miyaura Reactions - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/bfb4a6c3-c50c-4a13-8cb3-dc6f98488aea/Screenshot+2025-09-22+at+14.45.22.png Blog - Advantages and Challenges of Cross-Coupling Reactions and Recent Progress in Suzuki–Miyaura Reactions - Make it stand out Table 1. Recent Mechanistic Insights into Suzuki–Miyaura Cross-Coupling (2024–2025) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1c12378e-1cbd-4da0-aeee-7f2ad44e7cef/Screenshot+2025-09-22+at+14.47.30.png Blog - Advantages and Challenges of Cross-Coupling Reactions and Recent Progress in Suzuki–Miyaura Reactions - Make it stand out Table 2. Recent Advances in Ligand Design and Selection for Suzuki–Miyaura Cross-Coupling (2024–2025) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f4fb336a-4c41-4b4d-9d17-824370d92725/Screenshot+2025-09-22+at+11.13.44.png Blog - Advantages and Challenges of Cross-Coupling Reactions and Recent Progress in Suzuki–Miyaura Reactions - Make it stand out Table 3. Recent Advances in Boron Reagent Development for Suzuki–Miyaura Couplings (2023–2025) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/763d04e9-803d-4e5f-8528-fbb9189bb117/Screenshot+2025-09-22+at+15.45.44.png Blog - Advantages and Challenges of Cross-Coupling Reactions and Recent Progress in Suzuki–Miyaura Reactions - Make it stand out Table 3. Recent Advances in Boron Reagent Development for Suzuki–Miyaura Couplings (2023–2025) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ff59c438-f773-4849-8b5c-1d7f931d6085/Screenshot+2025-09-22+at+15.49.46.png Blog - Advantages and Challenges of Cross-Coupling Reactions and Recent Progress in Suzuki–Miyaura Reactions - Make it stand out Table 4. Advances in Reaction Media, Catalysis, and Scale-Up for Suzuki–Miyaura Couplings (2024–2025) https://www.chemical.ai/blog/humanai-synergy-in-retrosynthetic-analysis-and-route-optimization-of-balinatunfib monthly 0.5 2025-09-13 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/840536db-fcd5-44ec-af5a-714c37c9bdc1/Screenshot+2025-09-11+at+14.40.28.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 1. Crystal structure of the HUMAN TNF-ALPHA IN COMPLEX WITH CMPD 4 (PDB: 7JRA). Balinatunfib structure. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/fef4bc03-5cb2-4443-9a8e-418f775984b4/Screenshot+2025-09-11+at+14.43.40.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 2. Representative Chemical Structures of TNF-α small-molecule inhibitors https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/43da00c2-ed99-483c-85b6-8924cc48d4ec/Screenshot+2025-09-11+at+14.51.24.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 3. Synthetic Sequence for Fragment 1 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f2695c62-0346-4fe6-9a41-50f1cd7e1da4/Screenshot+2025-09-11+at+14.53.34.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 4. Synthetic Sequence for Fragment 1 (continued) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/07e6c36c-43cf-42d7-8306-edfbdca1e286/Screenshot+2025-09-11+at+14.55.56.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 5. Synthetic Sequence for Fragment 1 and final cross-coupling/deprotection sequence that led to balinatunfib https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f60b732c-6b67-45fa-bf1d-58f37b87c6b4/Screenshot+2025-09-11+at+15.04.59.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 6. ChemAIRS-Driven Synthesis of Balinatunfib. Route 001 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2f01c043-d454-4b79-9aed-af243c405a1f/Screenshot+2025-09-11+at+15.07.07.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 7. ChemAIRS-Driven Synthesis of Balinatunfib. Hybrid route combining R002 and R006 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/d2a2a2b4-70ca-4d33-9911-4e3bcdffd2d6/Screenshot+2025-09-11+at+15.09.18.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 8. Two-Step Synthesis of Mesylate 3a from Cyclobutanone 1b https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/469428e8-8376-4466-a919-a26254396eca/Screenshot+2025-09-11+at+15.11.21.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 9. Synthesis of 5a via Flow-Based Azidation/Reduction and Subsequent Two-Step Elaboration to 10b https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ddb805c5-0d21-4159-a9c9-2c95eecd4de4/Screenshot+2025-09-11+at+15.12.39.png Blog - Human–AI Synergy in Retrosynthetic Analysis and Route Optimization of Balinatunfib - Make it stand out Figure 10: Final Steps in the Synthesis of Balinatunfib https://www.chemical.ai/blog/bridging-biology-and-chemistry-bcl6-bms-986458-and-ai-predicted-routes-to-scalable-degraders monthly 0.5 2025-09-05 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a7767ec8-bbd8-4dcc-9fbf-30d0813532b2/Screenshot+2025-08-26+at+12.22.40%E2%80%AFPM.png Blog - Bridging Biology and Chemistry: BCL6, BMS-986458, and AI-Predicted Routes to Scalable Degraders - Make it stand out Figure 1. Crystal structure of the BCL6 BTB domain dimer (PDB: 1R28). Ribbon diagram representation. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7a08d077-9c34-4d60-a0d3-51ee0c4bc908/10.1021-acs.jmedchem.5c00485Figure1.pptx+%28800+x+600+px%29.jpg Blog - Bridging Biology and Chemistry: BCL6, BMS-986458, and AI-Predicted Routes to Scalable Degraders - Make it stand out Figure 2. Representative Chemical Structures of BCL6 Inhibitors and Degraders https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/81b0da10-6b6a-4ca1-b427-2c44cc8b5333/10.1021-acs.jmedchem.5c00485Figure1.pptx+%28800+x+600+px%29.png Blog - Bridging Biology and Chemistry: BCL6, BMS-986458, and AI-Predicted Routes to Scalable Degraders - Make it stand out Figure 3. BMS-986458: oral cereblon-recruiting, ligand-directed BCL6 degrader https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/9a698f09-5509-4dc1-90f1-4bfb6994ebc4/10.1021-acs.jmedchem.5c00485Figure1.pptx+%28800+x+600+px%29+2.44.30%E2%80%AFPM.png Blog - Bridging Biology and Chemistry: BCL6, BMS-986458, and AI-Predicted Routes to Scalable Degraders - Make it stand out Figure 4. Construction of the indazole–piperidine-2,6-dione motif (as described in WO 2023212147A1) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/dad6a0c8-943c-4cfb-b90b-6645c839fa34/10.1021-acs.jmedchem.5c00485Figure1.pptx+%28800+x+600+px%29.png Blog - Bridging Biology and Chemistry: BCL6, BMS-986458, and AI-Predicted Routes to Scalable Degraders - Make it stand out Fig. 5: Exemplary ChemAIRS-predicted synthetic route to BMS-986458 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/18ef1e14-81ec-409f-b898-c7ba0dbdb0c3/10.1021-acs.jmedchem.5c00485Figure1.pptx+%28800+x+600+px%29+3.07.05%E2%80%AFPM.png Blog - Bridging Biology and Chemistry: BCL6, BMS-986458, and AI-Predicted Routes to Scalable Degraders - Make it stand out Fig. 6: Regioselective zincation of indazole precursors https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4329e5f7-e043-41a4-9384-e382b79478dc/10.1021-acs.jmedchem.5c00485Figure1.pptx+%28800+x+600+px%29+4.31.55%E2%80%AFPM.png Blog - Bridging Biology and Chemistry: BCL6, BMS-986458, and AI-Predicted Routes to Scalable Degraders - Make it stand out Fig. 7: Nickel-catalyzed photoredox coupling https://www.chemical.ai/blog/expanding-the-therapeutic-toolbox-new-modalities-for-modern-drug-hunters monthly 0.5 2025-09-03 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/cb44c7c5-950c-4b44-9429-57497ffdef0a/Screenshot+2025-08-15+at+09.10.13.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ffa96df2-b1b4-4c4b-b2d2-e87e04e76a7c/Screenshot+2025-08-15+at+09.12.20.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c0a93b10-916c-4b98-8270-9e4e8894c3cc/Screenshot+2025-08-15+at+09.15.07.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a23ccf37-6f66-4306-9187-adeaac5370d0/Screenshot+2025-08-15+at+09.19.31.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b8c6f7d1-c27f-42bd-ae09-f1996b4c1dfd/Screenshot+2025-08-15+at+09.21.39.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/04100ff7-8f0a-41b3-a4aa-a4f2082e8f4d/Screenshot+2025-08-15+at+09.23.28.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/bdf208c5-374d-4e5e-ba52-1f28489cafc8/Screenshot+2025-08-15+at+09.24.59.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/09b5dcbd-519d-4edf-be86-f6492b19daeb/Screenshot+2025-08-15+at+09.26.30.png Blog - Expanding the Therapeutic Toolbox: New Modalities for Modern Drug Hunters - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://www.chemical.ai/blog/enabling-retrosynthetic-planning-for-radiotheranostics-chemairs-driven-synthesis-of-psma-and-ntsr1-ligands monthly 0.5 2025-06-24 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e838fc8a-7259-4e9a-bc44-5cd65c830e5a/chemical-structure-of-%5B177lu%5Dlu-psma-617-pluvicto Blog - Enabling Retrosynthetic Planning for Radiotheranostics: ChemAIRS-Driven Synthesis of PSMA and NTSR1 Ligands - Chemical structure of [177Lu]Lu-PSMA-617 (Pluvicto™) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/df94fbd5-76d3-4fe0-a9f2-670aefb875da/chemairs-enabled-synthesis-of-psma-617 Blog - Enabling Retrosynthetic Planning for Radiotheranostics: ChemAIRS-Driven Synthesis of PSMA and NTSR1 Ligands - ChemAIRS-Enabled Synthesis of PSMA-617 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2df5f02d-ee75-4dd2-9100-e2cb485fc576/chemairs-provided-a-synthetic-pathway-for-accessing-commercial-adc-linker Blog - Enabling Retrosynthetic Planning for Radiotheranostics: ChemAIRS-Driven Synthesis of PSMA and NTSR1 Ligands - ChemAIRS provided a synthetic pathway for accessing commercial ADC linker https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/fd770109-7fdc-4f43-93d5-11292988b646/chemical-structure-of-%5B225ac%5D-fpi-2059 Blog - Enabling Retrosynthetic Planning for Radiotheranostics: ChemAIRS-Driven Synthesis of PSMA and NTSR1 Ligands - Chemical structure of [225Ac]-FPI-2059 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e97f7f1c-4979-4a00-af87-92c20f07afc7/chemairs-enabled-synthesis-of-ntsr-1%E2%80%93targeting-ligand Blog - Enabling Retrosynthetic Planning for Radiotheranostics: ChemAIRS-Driven Synthesis of PSMA and NTSR1 Ligands - ChemAIRS-Enabled Synthesis of NTSR-1–targeting ligand https://www.chemical.ai/blog/chemairs-driven-route-design-for-macrocyclic-3clpro-inhibitors-streamlining-access-to-promising-anti-coronavirus-therapeuticsep22 monthly 0.5 2025-06-12 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/cecb1ec5-0ff9-40fa-914d-912faff6c87a/modulators-of-coronavirus-3c-like-protease Blog - ChemAIRS-Driven Route Design for Macrocyclic 3CLpro Inhibitors: Streamlining Access to Promising Anti-Coronavirus Therapeutics_EP22 - Modulators of Coronavirus 3C-like Protease https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f5016016-4b7d-4308-9256-7d7a8af0a683/chemairs-enabled-scalable-synthesis-of-macrocyclic-compound-44-in-wo2025058977 Blog - ChemAIRS-Driven Route Design for Macrocyclic 3CLpro Inhibitors: Streamlining Access to Promising Anti-Coronavirus Therapeutics_EP22 - ChemAIRS-Enabled Scalable Synthesis of Macrocyclic Compound 44 in WO2025058977 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a5ef9220-875e-4d15-8b20-6a30df85b7ff/chemairs-enabled-scalable-synthesis-of-intermediate-16a-using-reductive-cyclization-strategy Blog - ChemAIRS-Driven Route Design for Macrocyclic 3CLpro Inhibitors: Streamlining Access to Promising Anti-Coronavirus Therapeutics_EP22 - ChemAIRS-Enabled Scalable Synthesis of Intermediate 16a using Reductive Cyclization strategy https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a4dd38ac-77bf-4071-8529-653ff364e02e/chemairs-enabled-scalable-synthesis-of-intermediate-16b-via-base-promoted-arylation Blog - ChemAIRS-Driven Route Design for Macrocyclic 3CLpro Inhibitors: Streamlining Access to Promising Anti-Coronavirus Therapeutics_EP22 - ChemAIRS-Enabled Scalable Synthesis of Intermediate 16b via based-promoted arylation https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/87ff2ed4-6509-474d-a5a0-da67f02f145d/chemairs-enabled-streamlined-synthesis-of-macrocyclic-compound-17-in-wo2025058977 Blog - ChemAIRS-Driven Route Design for Macrocyclic 3CLpro Inhibitors: Streamlining Access to Promising Anti-Coronavirus Therapeutics_EP22 - ChemAIRS-Enabled Streamlined Synthesis of Macrocyclic Compound 17 in WO2025058977 https://www.chemical.ai/blog/chemairs-in-action-accelerating-the-discovery-and-optimization-of-synthetic-routes-for-alks-2680-a-selective-orexin-2-receptor-agonist-developed-by-alkermesep21 monthly 0.5 2025-05-15 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/733fc239-fece-45ff-a7f4-bd6ee00fb51c/ALKS+2680+%28alixorexton%29 Blog - ChemAIRS in Action: Accelerating the Discovery and Optimization of Synthetic Routes for ALKS 2680, a Selective Orexin-2 Receptor Agonist developed by Alkermes_EP21 - ALKS 2680 (alixorexton) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7bf2a603-4f67-47c6-89ed-d6b798af699a/alkermes%27s-published-synthetic-route-to-alks-2680 Blog - ChemAIRS in Action: Accelerating the Discovery and Optimization of Synthetic Routes for ALKS 2680, a Selective Orexin-2 Receptor Agonist developed by Alkermes_EP21 - Alkermes's published synthetic route to ALKS 2680 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ef0c2e63-507c-4819-963b-511b3af4bfb6/chemairs-suggested-retrosynthesis-analysis-of-alks-2680 Blog - ChemAIRS in Action: Accelerating the Discovery and Optimization of Synthetic Routes for ALKS 2680, a Selective Orexin-2 Receptor Agonist developed by Alkermes_EP21 - ChemAIRS suggested Retrosynthesis Analysis of ALKS 2680 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c89d0c9c-d7c5-48d6-b96b-f90b068d2018/%22chemairs-generated-alternative-discovery-route-to-alks-2680 Blog - ChemAIRS in Action: Accelerating the Discovery and Optimization of Synthetic Routes for ALKS 2680, a Selective Orexin-2 Receptor Agonist developed by Alkermes_EP21 - ChemAIRS generated alternative Discovery Route to ALKS 2680 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a347acc1-1178-4476-a755-38c9b805a664/chemairs-suggested-scalable-synthetic-route-to-alks-2680 Blog - ChemAIRS in Action: Accelerating the Discovery and Optimization of Synthetic Routes for ALKS 2680, a Selective Orexin-2 Receptor Agonist developed by Alkermes_EP21 - ChemAIRS suggested Scalable Synthetic Route to ALKS 2680 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/34e5a168-2160-41bb-bdfb-82874d9cce14/chemairs-selected-commercially-available-bulk-starting-materials-for-alks-2680-production Blog - ChemAIRS in Action: Accelerating the Discovery and Optimization of Synthetic Routes for ALKS 2680, a Selective Orexin-2 Receptor Agonist developed by Alkermes_EP21 - ChemAIRS Selected Commercially Available Bulk Starting Materials for ALKS 2680 Production https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a793571a-b30e-4903-b152-d2f621f6e5aa/chemairs-suggested-scale-up-reaction-condition-for-the-cyclization-step Blog - ChemAIRS in Action: Accelerating the Discovery and Optimization of Synthetic Routes for ALKS 2680, a Selective Orexin-2 Receptor Agonist developed by Alkermes_EP21 - ChemAIRS suggested scale-up reaction condition for the cyclization step https://www.chemical.ai/blog/chemairs-driven-retrosynthesis-of-elironrasib-rmc-6291-a-next-gen-kras-g12con-inhibitorep19nbsp monthly 0.5 2025-09-05 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/280a1040-2a9f-40e1-973c-4620769592bb/rmc-6291-a-next-gen-kras-g12c-on-inhibitor-from-revolution-medicines Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - RMC-6291: A Next-Gen KRAS-G12C(ON) Inhibitor from Revolution Medicines https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7c725190-fae8-4362-a7cf-6ca5e94958bc/chemairs-retrosynthetic-strategy-toward-elironrasib-rmc-6291 Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - ChemAIRS Retrosynthetic Strategy Toward Elironrasib (RMC-6291) https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c1f5a1ee-21a2-45ea-b32e-487b19b4ce68/key-fragmentation-intermediates-for-elironrasib-retrosynthesis Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - Key fragmentation intermediates for Elironrasib retrosynthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3904d6a4-f46e-4632-96e2-d45f08ac066b/chemairs-generated-synthetic-pathway-for-fluoropiperidine-intermediate Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - ChemAIRS-Generated Synthetic Pathway for fluoropiperidine Intermediate https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/74164d39-f032-4fb1-a824-3bfae274b9a6/retrosynthetic-fragmentation-of-intermediate-25b-into-building-blocks-12a-12b-and-14b Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - Retrosynthetic fragmentation of intermediate 25b into building blocks 12a, 12b, and 14b. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/9356d2e6-e296-41a6-a96d-0ed6be3da1ed/chemairs-generated-synthetic-pathway-for-macrocyclic-intermediate-25b Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - ChemAIRS-Generated Synthetic Pathway for Macrocyclic Intermediate 25b https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/18401721-442c-4f70-903d-fcd2ee7cf3b0/cost-effective-route-to-s-methyl-hexahydropyridazine-3-carboxylate-chemairs-enabled-3-step-synthesis-avoids-procurement-challenges Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - Cost-effective route to (S)-Methyl hexahydropyridazine-3-carboxylate: ChemAIRS-enabled 3-step synthesis avoids procurement challenges https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/cca09c25-6006-4c90-8868-22322c68f9d0/chemairs-identified-potential-competing-side-reactions Blog - ChemAIRS-Driven Retrosynthesis of Elironrasib (RMC-6291): A Next-Gen KRAS-G12C(ON) Inhibitor_EP20 - ChemAIRS identified potential competing side reactions https://www.chemical.ai/blog/chemairs-optimizes-the-synthesis-of-novo-nordisks-glucose-sensitive-derivativesep19 monthly 0.5 2025-04-02 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0f3b1599-30f3-4b0f-ad4d-54821cc7828a/novo-nordisk%E2%80%99s-diboron-based-glucose-sensitive-insulins.png Blog - ChemAIRS Optimizes the Synthesis of Novo Nordisk’s Glucose-Sensitive Derivatives_EP19 - Novo Nordisk’s Diboron-Based Glucose-Sensitive Insulins https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1ac5590a-490e-40d9-8a45-a52873b0ab7d/chemairs-outlines-synthesis-strategies-for-diboron-based-glucose-sensitive-insulins.png Blog - ChemAIRS Optimizes the Synthesis of Novo Nordisk’s Glucose-Sensitive Derivatives_EP19 - ChemAIRS Outlines Synthesis Strategies for Diboron-Based Glucose-Sensitive Insulins https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/98f046f5-1e43-490d-a588-38075b579f03/chemairs-identified-a-potential-competing-side-reaction Blog - ChemAIRS Optimizes the Synthesis of Novo Nordisk’s Glucose-Sensitive Derivatives_EP19 - ChemAIRS identified a potential competing side reaction https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ee0921f3-3f5c-4003-a79f-32372b84d6c2/chemairs-optimized-synthesis-diboron-glucose-sensitive-derivatives Blog - ChemAIRS Optimizes the Synthesis of Novo Nordisk’s Glucose-Sensitive Derivatives_EP19 - ChemAIRS reveals optimized strategies for enhanced synthesis of Diboron-Based Glucose-Sensitive Derivatives https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/9335f713-0553-46ca-92a0-9b5ccc4fd7c1/chemairs-identified-alternative-borylation-conditions-to-enhance-reaction-performance Blog - ChemAIRS Optimizes the Synthesis of Novo Nordisk’s Glucose-Sensitive Derivatives_EP19 - ChemAIRS identified alternative borylation conditions to enhance reaction performance https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/53957ba1-c547-4dec-b02b-e1a746e770b6/chemairs-miyaura-borylation-optimization-b%E2%82%82neop%E2%82%82-ultra-low-pd Blog - ChemAIRS Optimizes the Synthesis of Novo Nordisk’s Glucose-Sensitive Derivatives_EP19 - ChemAIRS optimizes Miyaura borylation: B₂(neop)₂ replaces B₂Pin₂, enabling ultra-low Pd with Pd(PCy₃)₂Cl₂/base https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/d74c18c5-4a92-4a9c-aebc-243512275416/chemairs-optimized-parameters-scalable-synthesis Blog - ChemAIRS Optimizes the Synthesis of Novo Nordisk’s Glucose-Sensitive Derivatives_EP19 - ChemAIRS delivers optimized reaction parameters for robust and scalable synthesis https://www.chemical.ai/blog/lchemairs-to-investigate-synthetic-strategies-for-sgr-1505-a-malt1-inhibitor-from-schrodinger monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c3e7db3c-e854-421d-8fc7-ae5639f6cefb/sgr-1505-as-a-novel-therapeutic-approach-for-cancer-treatment Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for SGR-1505, a MALT1 inhibitor from Schrodinger_EP09 - SGR-1505 as a Novel Therapeutic Approach for Cancer Treatment https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e68fcb07-83d8-4a27-a8ae-b15ec8858808/chemairs-predicted-a-synthetic-pathway-for-an-sgr-1505 Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for SGR-1505, a MALT1 inhibitor from Schrodinger_EP09 - ChemAIRS predicted a synthetic pathway for an SGR-1505 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0a679f8a-45b2-47ab-ae09-814c5b447431/chemairs-suggested-two-reaction-conditions-for-intramolecular-cyclization Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for SGR-1505, a MALT1 inhibitor from Schrodinger_EP09 - ChemAIRS suggested two reaction conditions for intramolecular cyclization https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f2b37377-f4d7-4742-91b1-075711fa21f1/chemairs-proposed-an-alternative-synthetic-strategy-to-obtain-sgr-1505 Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for SGR-1505, a MALT1 inhibitor from Schrodinger_EP09 - ChemAIRS Proposed An alternative synthetic strategy to obtain SGR-1505 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/fc166565-18b0-4311-a376-38d863069f50/chemairs-suggested-reaction-conditions-for-asymmetric-methylation Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for SGR-1505, a MALT1 inhibitor from Schrodinger_EP09 - ChemAIRS Suggested reaction conditions for asymmetric methylation https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ac1e5b37-ca89-452f-8793-1c2ba938fd8e/alternative-substrates-involved-a-palladium-catalyzed-amination-and-a-transamidation Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for SGR-1505, a MALT1 inhibitor from Schrodinger_EP09 - Alternative substrates involved a palladium-catalyzed amination and a transamidation https://www.chemical.ai/blog/chemairs-to-explore-synthetic-strategies-of-ab521-an-hif-2-inhibitor-from-arcus-bioscience monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f18fc149-6f67-4918-9b25-ae5653f73870/targeting-hif-2%CE%B1-ab521-%28casdatifan%29-as-a-promising-antitumor-agent-in-cancer-therapy Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of AB521, an HIF-2⍺ inhibitor from Arcus Bioscience_EP10 - Targeting HIF-2α: AB521 (Casdatifan) as a Promising Antitumor Agent in Cancer Therapy https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/834e4b5f-d08a-459b-bdc6-b04ba35110e3/chemairs-predicted-a-synthetic-pathway-for-ab521 Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of AB521, an HIF-2⍺ inhibitor from Arcus Bioscience_EP10 - ChemAIRS predicted a synthetic pathway for AB521 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7bc490e7-e56e-4328-99f9-40a24c353b27/chemairs-proposed-an-alternative-way-to-synthesize-intermediate-7a-due-to-the-aldehyde-functionality Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of AB521, an HIF-2⍺ inhibitor from Arcus Bioscience_EP10 - ChemAIRS proposed An alternative way to synthesize intermediate 7a due to the aldehyde functionality https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/16616878-343c-4828-a0ca-440137a13bb7/potential-side-reactions-for-the-synthesis-of-intermediate-10b-in-ab521-synthesis Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of AB521, an HIF-2⍺ inhibitor from Arcus Bioscience_EP10 - Potential side reactions for the synthesis of intermediate 10b in AB521 synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/18b9cd49-c894-48db-ac4d-6ac69f8bb113/chemairs-proposed-alternative-synthetic-route-for-ab521 Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of AB521, an HIF-2⍺ inhibitor from Arcus Bioscience_EP10 - ChemAIRS proposed Alternative synthetic route for AB521 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/eafc748a-9c6f-492a-a297-02ad18e1567e/reference-reactions-for-the-enantioselective-mono-fluorination-to-intermediate-3a Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of AB521, an HIF-2⍺ inhibitor from Arcus Bioscience_EP10 - Reference reactions for the enantioselective mono-fluorination to intermediate 3a https://www.chemical.ai/blog/streamlining-the-synthesis-of-novartis-wrn-inhibitor-hro761-with-chemairs-a-promising-therapeutic-for-msi-cancers monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/458c7660-1701-4bb3-892c-74179bd6d835/novartis%E2%80%99-wrn-inhibitor-hro761-a-promising-therapeutic-for-msi-cancers Blog - Streamlining the Synthesis of Novartis’ WRN Inhibitor HRO761 with ChemAIRS: A Promising Therapeutic for MSI Cancers_EP05 - Novartis’ WRN Inhibitor HRO761, A Promising Therapeutic for MSI Cancers https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c4709c0b-492c-4fef-a594-3ad54424ea0c/chemairs-predicted-a-synthetic-pathway-for-novartis%27s-wrn-inhibitor-hro761-closely-aligned-with-the-published-route Blog - Streamlining the Synthesis of Novartis’ WRN Inhibitor HRO761 with ChemAIRS: A Promising Therapeutic for MSI Cancers_EP05 - ChemAIRS predicted a synthetic pathway for Novartis's WRN inhibitor HRO761, closely aligned with the published route https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/fb580df3-5f78-4c06-ab19-94c899f1ff4c/chemairs-identified-side-reaction-risk-for-the-last-step-synthesis-of-hro761 Blog - Streamlining the Synthesis of Novartis’ WRN Inhibitor HRO761 with ChemAIRS: A Promising Therapeutic for MSI Cancers_EP05 - ChemAIRS identified side reaction risk for the last-step synthesis of HRO761 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/d0b80828-ede1-42f1-bb56-582b2140b87f/chemairs-suggested-an-alternative-synthetic-pathway-for-wrn-inhibitor-hro761-to-mitigate-final-step-risks Blog - Streamlining the Synthesis of Novartis’ WRN Inhibitor HRO761 with ChemAIRS: A Promising Therapeutic for MSI Cancers_EP05 - ChemAIRS suggested an alternative synthetic pathway for WRN inhibitor HRO761 to mitigate final step risks https://www.chemical.ai/blog/chemairs-to-unveil-synthetic-strategies-for-selective-cannabinoid-receptor-2-inverse-agonists monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/64586fe9-ab6c-4af4-81d7-d677d9c13a62/advances-in-cb2-inverse-agonists-exploring-therapeutic-potential-and-selectivity Blog - Leveraging ChemAIRS to Unveil Synthetic Strategies for Selective Cannabinoid Receptor 2 Inverse Agonists_EP11 - Advances in CB2 Inverse Agonists: Exploring Therapeutic Potential and Selectivity https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a75de9e5-cafb-4fc5-a669-228670fc143c/chemairs-predicted-a-synthetic-pathway-for-cb2r-inverse-agonists Blog - Leveraging ChemAIRS to Unveil Synthetic Strategies for Selective Cannabinoid Receptor 2 Inverse Agonists_EP11 - ChemAIRS predicted a synthetic pathway for CB2R inverse agonists https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ce44a5a9-2772-40ce-95b1-7747fb6149bd/chemairs-identified-potential-side-reaction-for-the-synthesis-of-intermediate-9a Blog - Leveraging ChemAIRS to Unveil Synthetic Strategies for Selective Cannabinoid Receptor 2 Inverse Agonists_EP11 - ChemAIRS identified Potential side reaction for the synthesis of intermediate 9a https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e68185f7-4b49-4688-9fdb-d9b155a48e65/chemairs-proposed-alternative-synthetic-route-for-cb2r-inverse-agonists Blog - Leveraging ChemAIRS to Unveil Synthetic Strategies for Selective Cannabinoid Receptor 2 Inverse Agonists_EP11 - ChemAIRS Proposed Alternative synthetic route for CB2R inverse agonists https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/51aa2fe0-0928-4686-8789-122ce956174a/chemairs-identified-potential-side-reaction-for-the-synthesis-of-intermediate-4a Blog - Leveraging ChemAIRS to Unveil Synthetic Strategies for Selective Cannabinoid Receptor 2 Inverse Agonists_EP11 - ChemAIRS identified Potential side reaction for the synthesis of intermediate 4a https://www.chemical.ai/blog/chemairs-to-investigate-synthetic-strategies-for-chiral-spirocyclic-isoxazolone-a-vital-building-block-in-a-boehringer-ingelheim-drug-development-program monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/51534280-5856-439c-8764-232b592bbb6a/chiral-spirocyclic-isoxazolone-a-vital-building-block-in-a-boehringer-ingelheim-drug-development-program Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Chiral Spirocyclic Isoxazolone, a Vital Building Block in a Boehringer Ingelheim Drug Development Program_EP08 - Chiral Spirocyclic Isoxazolone, a Vital Building Block in a Boehringer Ingelheim Drug Development Program https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/79b68c9e-05dc-4ed4-a651-ba3d733d4026/chemairs-predicted-a-synthetic-pathway-for-spirocyclic-isoxazolone-starting-from-a-commercially-available-starting-material-1b Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Chiral Spirocyclic Isoxazolone, a Vital Building Block in a Boehringer Ingelheim Drug Development Program_EP08 - ChemAIRS predicted a synthetic pathway for spirocyclic isoxazolone, starting from a commercially available starting material 1b https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/208ee12b-7353-4c39-85f0-176f6acabb01/suggested-reaction-conditions-for-scaling-up-intermediate-3a Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Chiral Spirocyclic Isoxazolone, a Vital Building Block in a Boehringer Ingelheim Drug Development Program_EP08 - ChemAIRS Suggested reaction conditions for scaling up intermediate 3a https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/bbd06cb9-b4cd-4508-90d4-307a0a7f3ecb/potential-side-reaction-for-the-synthesis-of-3a Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Chiral Spirocyclic Isoxazolone, a Vital Building Block in a Boehringer Ingelheim Drug Development Program_EP08 - Potential side reaction for the synthesis of 3a https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/62e73991-27c9-479f-a3a0-5a0f9375e54d/chemairs-proposed-alternative-synthetic-route-for-spirocyclic-isoxazolone Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Chiral Spirocyclic Isoxazolone, a Vital Building Block in a Boehringer Ingelheim Drug Development Program_EP08 - ChemAIRS proposed Alternative synthetic route for spirocyclic isoxazolone https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/df899b74-7d88-4413-af89-54ad50af51f1/chemairs-identified-potential-side-reaction-for-the-synthesis-of-4a Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Chiral Spirocyclic Isoxazolone, a Vital Building Block in a Boehringer Ingelheim Drug Development Program_EP08 - ChemAIRS identified Potential side reaction for the synthesis of 4a https://www.chemical.ai/blog/chemairs-to-explore-synthetic-strategies-of-azabenzimidazolone-a-potent-v1-integrin-antifibrotic-by-takeda monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/34409b21-963a-4083-b724-b3db7e4dbcb9/azabenzimidazolone-as-a-potent-antifibrotic-agent-targeting-%CE%B1v%CE%B21-integrin Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of Azabenzimidazolone: A Potent αvβ1 Integrin Antifibrotic by Takeda_07 - Azabenzimidazolone as a Potent Antifibrotic Agent Targeting αvβ1 Integrin https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/38a63b68-7812-4af0-abb1-9da8ad9f3fc0/chemairs-proposed-a-synthetic-pathway-for-azabenzimidazolone-recommending-the-ring-closing-reaction-as-the-final-step Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of Azabenzimidazolone: A Potent αvβ1 Integrin Antifibrotic by Takeda_07 - ChemAIRS proposed a synthetic pathway for Azabenzimidazolone, recommending the ring-closing reaction as the final step https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ddda03e1-a25c-43b9-9fdc-1350ab2bb514/chemairs-detected-potential-side-reactions-during-the-synthesis-of-intermediate-7a-in-azabenzimidazolone-synthesis Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of Azabenzimidazolone: A Potent αvβ1 Integrin Antifibrotic by Takeda_07 - ChemAIRS detected potential side reactions during the synthesis of intermediate 7a in Azabenzimidazolone synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6fe1d497-858a-4738-9d8d-a8447a27749f/alternative-synthetic-route-for-azabenzimidazolone-suggested-by-chemairs Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of Azabenzimidazolone: A Potent αvβ1 Integrin Antifibrotic by Takeda_07 - Alternative Synthetic Route for Azabenzimidazolone suggested by ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/5094da62-bdb2-4fdf-8b1d-d4d0be3b9a61/chemairs-reaction-site-analysis-for-the-synthesis-of-intermediate-7a Blog - Utilizing ChemAIRS to Explore Synthetic Strategies of Azabenzimidazolone: A Potent αvβ1 Integrin Antifibrotic by Takeda_07 - ChemAIRS reaction site analysis for the synthesis of intermediate 7a https://www.chemical.ai/blog/chemairs-to-investigate-synthesis-strategies-of-ox2r-modulator-a-vertex-pharmaceuticals-approach-to-narcolepsy-treatment monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2e9ea6c3-a957-419c-91f1-ef1291ef5c18/macrocyclic-amine-modulators-targeting-ox2r-a-promising-narcolepsy-treatment Blog - Use ChemAIRS to Investigate Synthesis Strategies of OX2R Modulator, a Vertex Pharmaceuticals' Approach to Narcolepsy Treatment_EP06 - Macrocyclic Amine Modulators Targeting OX2R: A Promising Narcolepsy Treatment https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e0b1c026-a14b-4e62-8c26-6b9f45d7f15b/chemairs-predicted-a-synthetic-pathway-for-an-ox2r-modulator-which-closely-aligns-with-vertex%27s-patented-report Blog - Use ChemAIRS to Investigate Synthesis Strategies of OX2R Modulator, a Vertex Pharmaceuticals' Approach to Narcolepsy Treatment_EP06 - ChemAIRS predicted a synthetic pathway for an OX2R modulator, which closely aligns with Vertex's patented report https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a0ed507c-195a-464d-929f-8b9025a1d6e5/proposed-cost-effective-synthetic-strategy-for-13a-from-chemairs Blog - Use ChemAIRS to Investigate Synthesis Strategies of OX2R Modulator, a Vertex Pharmaceuticals' Approach to Narcolepsy Treatment_EP06 - Proposed cost-effective synthetic strategy for 13a from ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3572c7d5-1840-4718-81c7-050d48d941c5/alternative-synthetic-routes-for-the-ox2r-modulator-initiated-with-the-preparation-of-two-chiral-intermediates Blog - Use ChemAIRS to Investigate Synthesis Strategies of OX2R Modulator, a Vertex Pharmaceuticals' Approach to Narcolepsy Treatment_EP06 - Alternative Synthetic Routes for the OX2R Modulator, initiated with the preparation of two chiral intermediates https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/302ac56f-bbeb-4798-962f-572fd17c7987/alternative-synthetic-routes-for-ox2r-modulator-featuring-the-formation-of-the-macrocyclic-molecule-through-intramolecular-etherification Blog - Use ChemAIRS to Investigate Synthesis Strategies of OX2R Modulator, a Vertex Pharmaceuticals' Approach to Narcolepsy Treatment_EP06 - Alternative Synthetic Routes for OX2R Modulator, featuring the formation of the macrocyclic molecule through intramolecular etherification https://www.chemical.ai/blog/rapidly-identifying-alternative-synthetic-routes-for-mercks-kras-g12c-inhibitor monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1833ab4c-3bc5-49d4-b07e-43abac4afd49/merck%27s-discovery-of-selective-g12c-inhibitors-for-kras-mutant-cancers Blog - Rapidly Identifying Alternative Synthetic Routes for Merck's KRAS G12C Inhibitor_EP04 - Merck's Discovery of Selective G12C Inhibitors for KRAS-Mutant Cancers https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/aa3cacc4-6064-4ab7-bf18-95f03c28fe37/chemairs-predicted-a-synthetic-pathway-for-merck%27s-kras-inhibitor-closely-aligned-with-the-published-route Blog - Rapidly Identifying Alternative Synthetic Routes for Merck's KRAS G12C Inhibitor_EP04 - ChemAIRS predicted a synthetic pathway for Merck's KRAS inhibitor, closely aligned with the published route https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/97955692-f4b4-4d42-a170-94737ddf24ab/chemairs-suggested-an-alternative-synthetic-route-for-6b-a-key-intermediate-for-route-optimization-of-kras-inhibitor Blog - Rapidly Identifying Alternative Synthetic Routes for Merck's KRAS G12C Inhibitor_EP04 - ChemAIRS suggested an alternative synthetic route for 6b, a key intermediate for route optimization of KRAS inhibitor https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/60df85f1-15c8-4774-9b33-1ddb61bb668a/chemairs-identified-functional-group-compatibility-risk-for-compound-3a-and-suggested-alternative-reaction-conditions Blog - Rapidly Identifying Alternative Synthetic Routes for Merck's KRAS G12C Inhibitor_EP04 - ChemAIRS identified functional group compatibility risk for compound 3a and suggested alternative reaction conditions https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/046498d5-60a0-4b60-949f-7ab8899536e9/chemairs-analyzed-the-reaction-site-for-compound-3a-to-advise-users-on-potential-side-reactions Blog - Rapidly Identifying Alternative Synthetic Routes for Merck's KRAS G12C Inhibitor_EP04 - ChemAIRS analyzed the reaction site for compound 3a to advise users on potential side reactions https://www.chemical.ai/blog/exploring-the-synthesis-of-janssens-rsv-f-inhibitor-usingchemairs monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/08d85f86-c3b3-41be-bc21-6e02af6a2687/spiro-azetidine-oxindole-sulfonamide-derivative-exhibiting-potent-inhibition-of-the-rsv-fusion-protein Blog - Exploring the Synthesis of Janssen's RSV-F Inhibitor Using ChemAIRS_EP03 - Spiro-azetidine oxindole sulfonamide derivative, exhibiting potent inhibition of the RSV fusion protein https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b8cfb86a-1f55-491e-b18f-cec4ce1b042c/chemairs-proposed-retrosynthetic-strategy-for-spiro-azetidine-oxindole-sulfonamide-a-potent-rsv-fusion-inhibitor Blog - Exploring the Synthesis of Janssen's RSV-F Inhibitor Using ChemAIRS_EP03 - ChemAIRS Proposed Retrosynthetic Strategy for Spiro-Azetidine Oxindole Sulfonamide, a Potent RSV Fusion Inhibitor https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/abaad3ff-d43f-451c-bc77-3fb94b5a0572/chemairs-identified-cost-efficient-synthetic-route-to-spiro-azetidine-oxindole-sulfonamide Blog - Exploring the Synthesis of Janssen's RSV-F Inhibitor Using ChemAIRS_EP03 - ChemAIRS-Identified Cost-Efficient Synthetic Route to Spiro-Azetidine Oxindole Sulfonamide https://www.chemical.ai/blog/chemairs-to-investigate-synthesis-strategy-of-prmt5-inhibitor-from-gilead-sciences monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c3531d53-7a87-4291-a9c5-d840891002ac/prmt5-has-emerged-as-a-promising-and-valuable-target-for-cancer-epigenetic-therapy Blog - Utilizing ChemAIRS to investigate synthesis strategy of PRMT5 inhibitor from Gilead Sciences_EP01 - PRMT5 has emerged as a promising and valuable target for cancer epigenetic therapy https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1ba1879f-ac6b-4a94-bcae-ba7868f26510/chemairs%27-proposed-synthetic-pathway-for-prmt5-inhibitor Blog - Utilizing ChemAIRS to investigate synthesis strategy of PRMT5 inhibitor from Gilead Sciences_EP01 - ChemAIRS' Proposed synthetic Pathway for PRMT5 inhibitor https://www.chemical.ai/blog/optimizing-synthetic-strategies-of-genentechs-epb-inhibitor-with-chemairs monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3d9e572b-aab7-4035-8685-101ba9af5670/emopamil-binding-protein-%28ebp%29-as-a-promising-in-vivo-tool-molecule-for-further-assessment-of-potential-remyelination-therapies Blog - Optimizing Synthetic Strategies of Genentech's EPB inhibitor with ChemAIRS_EP02 - emopamil binding protein (EBP) as a promising in vivo tool molecule for further assessment of potential remyelination therapies https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/40808ea4-ec0b-4436-b219-497792f80f19/Scheme+1.PNGchemairs-proposed-synthetic-pathway-to-an-ebp-inhibitor Blog - Optimizing Synthetic Strategies of Genentech's EPB inhibitor with ChemAIRS_EP02 - ChemAIRS' Proposed Synthetic Pathway to an EBP inhibitor https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e4ed0580-9b09-4401-9b65-e36938699684/chemairs-proposed-alternative-synthetic-pathway-to-an-ebp-inhibitor-with-a-different-set-of-starting-materials Blog - Optimizing Synthetic Strategies of Genentech's EPB inhibitor with ChemAIRS_EP02 - ChemAIRS’ Proposed Alternative Synthetic Pathway to an EBP inhibitor, With a different set of starting materials https://www.chemical.ai/blog/chemairs-to-accelerate-discovery-of-synthetic-strategies-for-kt474-a-selective-orally-bioavailable-heterobifunctional-irak4-degrader-from-kymera-therapeutics monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3c18abce-2142-4ed4-b691-13417b7c2437/KT-474-a+first-in-class-selective-and-orally-bioavailable-heterobifunctional-IRAK4-degrader.png Blog - Using ChemAIRS to Accelerate Discovery of Synthetic Strategies for KT474: A Selective, Orally Bioavailable Heterobifunctional IRAK4 Degrader from Kymera Therapeutics_EP14 - KT-474: A First-in-Class IRAK4 Degrader Advancing Autoimmune and Inflammatory Disease Therapies https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/abfd6b86-e213-4bf8-aced-7304048c62eb/chemAIRS-predicted-a-synthetic-pathway-for-KT-474.png Blog - Using ChemAIRS to Accelerate Discovery of Synthetic Strategies for KT474: A Selective, Orally Bioavailable Heterobifunctional IRAK4 Degrader from Kymera Therapeutics_EP14 - ChemAIRS predicted a synthetic pathway for KT-474, which closely parallels the synthetic pathway previously reported by Kymera Therapeutics https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/08ed3cc2-3dd2-449a-9360-0487acd474c7/chemairs-proposed-alternative-reaction-conditions-to-kt-474.png Blog - Using ChemAIRS to Accelerate Discovery of Synthetic Strategies for KT474: A Selective, Orally Bioavailable Heterobifunctional IRAK4 Degrader from Kymera Therapeutics_EP14 - Make it stand out Whatever it is, the way you tell your story online can make all the difference. https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e4dcb0a2-2754-4fae-b877-44428c9f05da/chemairs-proposed-alternative-synthetic-pathway-to-kt-474.png Blog - Using ChemAIRS to Accelerate Discovery of Synthetic Strategies for KT474: A Selective, Orally Bioavailable Heterobifunctional IRAK4 Degrader from Kymera Therapeutics_EP14 - ChemARIS Proposed Alternative synthetic pathway to KT-474 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ba0dfe93-745b-4b3f-b975-d61fd32946fe/chemairs-identified-a-potential-side-reaction-in-the-coupling-step-of-KT-474-and-proposed-optimireaction-conditions-to-minimize-its-occurrence.png Blog - Using ChemAIRS to Accelerate Discovery of Synthetic Strategies for KT474: A Selective, Orally Bioavailable Heterobifunctional IRAK4 Degrader from Kymera Therapeutics_EP14 - ChemAIRS identified a potential side reaction in the final coupling step to KT-474 and proposed optimized reaction conditions to minimize its occurrence. https://www.chemical.ai/blog/enhancing-synthetic-pathways-and-tackling-impurities-how-chemairs-supports-the-synthesis-of-4-chloro-123-triazole-for-milvexian monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0e79fb6b-fb1c-46bd-bf8d-c4b56e962a1b/4-chloro-1%2C2%2C3-triazole-a-critical-intermediate-in-milvexian-synthesis.png Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - 4-chloro-1,2,3-triazole, a critical intermediate in Milvexian synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1cdb5322-9cad-4f80-bb59-4c532d441c74/chemairs-predicts-a-synthetic-pathway-for-4-chloro-1%2C2%2C3-triazole-in-milvexian-synthesis-aligned-with-bristol-myers-squibb%27s-approach Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - ChemAIRS Predicts a Synthetic Pathway for 4-Chloro-1,2,3-Triazole in Milvexian synthesis which is Aligned with Bristol Myers Squibb's Approach https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3c4259ee-b55f-4c3e-979e-4b524380db14/discover-chemairs%27-proposed-synthetic-route-for-4-chloro-1%2C2%2C3-triazole-in-milvexian-synthesis-highlighting-triazole-enabled-ruthenium-catalyzed-c-h-arylations.png Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - Discover ChemAIRS' proposed synthetic route for 4-Chloro-1,2,3-Triazole in Milvexian synthesis, highlighting triazole-enabled ruthenium-catalyzed C–H arylations https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4a8e8778-3255-41fe-bd44-42836821f8e8/chemairs-identifies-potential-side-reactions-as-risk-items-in-milvexian-synthesis.png Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - ChemAIRS identifies potential side reactions as risk items in Milvexian synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/922512e0-d2ad-434a-8556-f4dd0cf839d0/impurity-identified-in-the-suzuki-miyaura-coupling-step-as-reported-by-bristol-myers-squibb-in-milvexian-synthesis.jpg Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - Impurity identified in the Suzuki-Miyaura coupling step, as reported by Bristol Myers Squibb in Milvexian synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/42ee762f-cefe-45a4-a03f-d9f18774c0e8/chemairs-predicts-impurity-structures-for-the-suzuki-miyaura-coupling-step-in-milvexian-synthesis.png Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - ChemAIRS predicts impurity structures for the Suzuki-Miyaura coupling step in Milvexian synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2eae142e-0ae2-4bd9-a043-c60c47867cc9/impurity-identified-in-the-chlorination-step-as-reported-by-bristol-myers-squibb-in-milvexian-synthesis.jpg Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - Impurity identified in the chlorination step, as reported by Bristol Myers Squibb in Milvexian synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/94ea4113-a69a-4abd-8601-14dbd69b3ddb/chemairs-predicts-impurity-structures-for-the-chlorination-step-in-milvexian-synthesis.png Blog - Enhancing Synthetic Pathways and Tackling Impurities: How ChemAIRS Supports the Synthesis of 4-Chloro-1,2,3-Triazole for Milvexian_EP15 - ChemAIRS predicts impurity structures for the chlorination step in Milvexian synthesis https://www.chemical.ai/blog/chemairs-to-explore-synthetic-strategies-for-bay-2413555-a-bayer-therapeutic-candidate-targeting-heart-failure monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b5e8158b-c27a-4915-88e0-a966efeced7f/bay-2413555-a-selective-and-reversible-m%E2%82%82-receptor-m2r-positive-allosteric-modulator-pam.png Blog - Utilizing ChemAIRS to Explore Synthetic Strategies for BAY 2413555: A Bayer Therapeutic Candidate Targeting Heart Failure_EP16 - BAY 2413555, a selective and reversible M₂ receptor (M2R) positive allosteric modulator (PAM), was developed to enhance parasympathetic signaling and restore cardiac autonomic balance https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/96cb34f5-3a39-420a-936a-580a71793978/chemairs-proposed-retrosynthetic-strategy-for-bay-2413555.png Blog - Utilizing ChemAIRS to Explore Synthetic Strategies for BAY 2413555: A Bayer Therapeutic Candidate Targeting Heart Failure_EP16 - ChemAIRS-Proposed Retrosynthetic Strategy for BAY 2413555 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b8dada00-32a8-4142-b170-872eaf78436a/chemairs-proposed-additional-strategies-for-the-pentafluoroalkyl-amine-an-intermediate-in-synthesis-of-bay-2413555.png Blog - Utilizing ChemAIRS to Explore Synthetic Strategies for BAY 2413555: A Bayer Therapeutic Candidate Targeting Heart Failure_EP16 - ChemAIRS-Proposed Additional Atrategies for the Pentafluoroalkyl Amine, an intermediate in synthesis of BAY 2413555 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3988e79c-27ba-4722-b9b0-5e6dfdd509e2/chemairs-suggested-alternative-pathway-to-bay-2413555-where-amide-formation-was-strategically-shifted-earlier-in-the-sequence.png Blog - Utilizing ChemAIRS to Explore Synthetic Strategies for BAY 2413555: A Bayer Therapeutic Candidate Targeting Heart Failure_EP16 - ChemAIRS-Suggested Alternative Pathway to BAY 2413555, where amide formation was strategically shifted earlier in the sequence https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0b1098ae-f6a0-4928-8995-178f8f0d8ea5/chemairs-proposed-optimized-scale-up-conditions-for-the-amidation-step.png Blog - Utilizing ChemAIRS to Explore Synthetic Strategies for BAY 2413555: A Bayer Therapeutic Candidate Targeting Heart Failure_EP16 - ChemAIRS Proposed Optimized Scale-Up Conditions for the amidation step in synthesis of BAY 2413555 https://www.chemical.ai/blog/chemairs-to-investigate-synthetic-approaches-for-azetidine-based-v6-integrin-inhibitors-core-modifications-of-gsk3335103 monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e9a3f3bf-f498-458b-9e08-759ce5203b65/%CE%B1v%CE%B26-inhibitors-from-gsk-building-on-their-earlier-compounds-gsk3008348-and-gsk3335103.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - αvβ6 inhibitors from GSK, building on their earlier compounds GSK3008348 and GSK3335103 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0e849249-b021-457c-81f6-76aed2f79654/chemairs-proposed-synthetic-strategy-for-gsk%27s-azetidine-based-%CE%B1v%CE%B26-integrin-inhibitors.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - ChemAIRS-Proposed Synthetic Strategy for GSK's Azetidine-Based αvβ6 Integrin Inhibitors https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ac455852-b557-40a8-ade9-cc1c3e74e13a/wittig-reaction-driven-synthesis-of-a-difluoroazetidine-intermediate.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - Wittig Reaction-Driven Synthesis of a Difluoroazetidine Intermediate https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1a118452-552a-4690-96b3-6aa2923638f6/horner%E2%80%93wadsworth%E2%80%93emmons-reaction-for-the-synthesis-of-a-fluoroazetidine-intermediate.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - Horner–Wadsworth–Emmons Reaction for the Synthesis of a Fluoroazetidine Intermediate https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/90459af2-a827-4927-82c1-7b4b1864131e/chemairs-identified-a-potential-side-reaction-in-the-conjugate-addition-of-arylboronic-acid-to-4-oxoisocrotonic-acid.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - ChemAIRS Identified a Potential Side Reaction in the conjugate addition of arylboronic acid to 4-oxoisocrotonic acid https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/decc4beb-9833-4b64-9cd9-9fc973e79785/chemairs%27-proposed-alternative-pathway-to-synthesize-diphosphorylated-intermediate-considering-safety-issue-of-starting-materials.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - ChemAIRS' proposed Alternative pathway to synthesize diphosphorylated intermediate, considering safety issue of starting materials https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/fa68108b-a106-430c-8159-16866d7faba4/chemairs-proposed-synthetic-strategy-for-gsk%27s-azetidine-based-%CE%B1v%CE%B26-integrin-inhibitors.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - ChemAIRS-Proposed Synthetic Strategy for GSK's Azetidine-Based αvβ6 Integrin Inhibitors https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e334bb06-bea5-46ee-be1a-4b32ffb9574b/chemairs-proposed-optimized-scale-up-conditions-for-a-reductive-amination.png Blog - Leveraging ChemAIRS to Investigate Synthetic Approaches for Azetidine-Based αvβ6 Integrin Inhibitors: Core Modifications of GSK3335103_EP17 - ChemAIRS Proposed Optimized Scale-Up Conditions for a reductive amination https://www.chemical.ai/blog/chemairs-to-investigate-synthesis-strategies-for-azd5462-a-promising-rxfp1-agonist-for-heart-failure-treatment monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/47a60d12-f028-478f-a6fa-0d514951a886/azd5462-a-small-molecule-mimetic-of-relaxin-h2-signaling-at-rxfp1-offering-promise-as-a-treatment-for-heart-failure.png Blog - Utilizing ChemAIRS to Investigate Synthesis Strategies for AZD5462: A Promising RXFP1 Agonist for Heart Failure Treatment_EP12 - AZD5462, a small-molecule mimetic of relaxin H2 signaling at RXFP1, offering promise as a treatment for heart failure https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4d33ab09-a2a0-47a2-bca4-bdb61f3e2f04/chemairs-predicted-a-19-step-synthetic-pathway-for-azd5462.png Blog - Utilizing ChemAIRS to Investigate Synthesis Strategies for AZD5462: A Promising RXFP1 Agonist for Heart Failure Treatment_EP12 - ChemAIRS predicted a 19-step synthetic pathway for AZD5462 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b9810f70-dd22-4f3d-9ed2-a9237c58eb18/chemairs-proposed-efficient-synthetic-route-for-1-methylcyclobutyl-methanamine.png Blog - Utilizing ChemAIRS to Investigate Synthesis Strategies for AZD5462: A Promising RXFP1 Agonist for Heart Failure Treatment_EP12 - ChemAIRS proposed efficient synthetic route for (1-methylcyclobutyl)methanamine https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/54ea9cd6-7b0f-4914-ac39-8cc25a8db749/chemairs%27-proposed-alternative-scale-up-conditions-in-coupling-reaction-for-one-intermediate-of-azd5462.png Blog - Utilizing ChemAIRS to Investigate Synthesis Strategies for AZD5462: A Promising RXFP1 Agonist for Heart Failure Treatment_EP12 - ChemAIRS' Proposed alternative scale-up conditions in coupling reactionfor one intermediate of AZD5462 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/82ec7eea-8eb6-4348-b852-2203f3370083/chemairs-predicted-possible-side-reaction-in-the-synthesis-of-azd5462.png Blog - Utilizing ChemAIRS to Investigate Synthesis Strategies for AZD5462: A Promising RXFP1 Agonist for Heart Failure Treatment_EP12 - ChemAIRS predicted Possible side reaction in the synthesis of AZD5462 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2a5fa18e-1e6d-45e8-88ec-b1da5bc1fc86/chemairs-proposed-alternative-synthetic-strategy-to-obtain-azd5462.png Blog - Utilizing ChemAIRS to Investigate Synthesis Strategies for AZD5462: A Promising RXFP1 Agonist for Heart Failure Treatment_EP12 - ChemAIRS proposed alternative synthetic strategy to obtain AZD5462 https://www.chemical.ai/blog/retrosynthetic-strategy-for-orforglipron-ly3502970-using-chemairs-developing-a-more-streamlined-and-efficient-synthetic-route-suggestion monthly 0.5 2025-09-03 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8ebb66c2-2fa5-4918-bd97-a6b2999854d4/orforglipron-ly3502970-an-orally-bioavailable-non-peptide-glp-1ra-eliminates-the-need-for-absorption-enhancers Blog - Enhancing the Retrosynthetic Strategy for Orforglipron (LY3502970) Using ChemAIRS: Developing a More Streamlined and Efficient Synthetic Route Suggestion_EP18 - Orforglipron (LY3502970), an orally bioavailable non-peptide GLP-1RA, eliminates the need for absorption enhancers https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b9a721aa-4c4c-437f-a0fc-9e8b4aa0c87d/chemairs%27-proposed-approach-for-the-synthesis-of-orforglipron Blog - Enhancing the Retrosynthetic Strategy for Orforglipron (LY3502970) Using ChemAIRS: Developing a More Streamlined and Efficient Synthetic Route Suggestion_EP18 - ChemAIRS' proposed approach for the synthesis of Orforglipron https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ea34b7f3-aac0-42c2-aeaf-68c31561c9c5/chemairs%27-proposed-synthetic-route-for-the-imidazol-2-one-intermediate-of-orforglipron Blog - Enhancing the Retrosynthetic Strategy for Orforglipron (LY3502970) Using ChemAIRS: Developing a More Streamlined and Efficient Synthetic Route Suggestion_EP18 - ChemAIRS' proposed synthetic route for the imidazol-2-one intermediate of Orforglipron https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/5f236196-5e41-478e-bfe4-cf3a69d6ce1d/chemairs%27-proposed-optimized-scale-up-conditions-of-orforglipron Blog - Enhancing the Retrosynthetic Strategy for Orforglipron (LY3502970) Using ChemAIRS: Developing a More Streamlined and Efficient Synthetic Route Suggestion_EP18 - ChemAIRS' Proposed Optimized Scale-Up Conditions of Orforglipron https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b0b5763b-4b8c-4dc4-99a1-ff06a2fc63a1/%22chemairs%27-proposed-synthetic-route-for-the-indole-2-carboxylic-acid-intermediate-of-orforglipron Blog - Enhancing the Retrosynthetic Strategy for Orforglipron (LY3502970) Using ChemAIRS: Developing a More Streamlined and Efficient Synthetic Route Suggestion_EP18 - ChemAIRS' proposed synthetic route for the indole-2-carboxylic acid intermediate of Orforglipron https://www.chemical.ai/blog/chemairs-to-investigate-synthetic-strategies-for-tetrahydrobenzoazepine-core-of-btk-inhibitor-biib091 monthly 0.5 2025-03-28 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6f337992-866e-4483-867f-3c79aa1a83cb/tetrahydrobenzoazepine-core-of-btk-inhibitor-biib091.png Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1f7cfbc9-4449-4760-93ee-0db36164bccb/chem-airs-proposed-synthetic-route-for-tetrahydrobenzoazepine-featuring-friedel-crafts-acylation-to-construct-the-benzazepine-core-from-an-n-boc-ketone.png Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - Chem AIRS Proposed synthetic route for Tetrahydrobenzoazepine, featuring Friedel-Crafts acylation to construct the benzazepine core from an N-Boc ketone https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0acea6b4-0a8c-4214-9cce-2e23e1bb1d5a/chemairs-proposed-synthetic-route-for-tetrahydrobenzoazepine-featuring-friedel-crafts-acylation-to-construct-the-benzazepine-core-from-an-n-boc-ketone Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - ChemAIRS Proposed synthetic route for Tetrahydrobenzoazepine, featuring Friedel-Crafts acylation to construct the benzazepine core from an N-Boc ketone https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1240ba65-0af2-4df1-8642-9a75208f10f5/proposed-synthetic-route-for-tetrahydrobenzoazepine-featuring-intramolecular-pd-catalyzed-heck-reaction-to-construct-the-benzazepine-core-from-an-n-boc-ketone.png Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - ChemAIRS Proposed synthetic route for Tetrahydrobenzoazepine, featuring Intramolecular Pd-Catalyzed Heck Reaction to construct the benzazepine core from an N-Boc ketone https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/d8ad4e9f-5d1c-4911-bf76-37fc2460c7f2/chemairs-proposed-synthetic-route-for-tetrahydrobenzoazepine-featuring-ester-aryl-halide-cyclization-to-construct-the-benzazepine-core-from-an-n-boc-ketone.png Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - ChemAIRS Proposed synthetic route for Tetrahydrobenzoazepine, featuring Ester-Aryl Halide Cyclization to construct the benzazepine core from an N-Boc ketone https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/00f8545a-727f-495d-8599-8cf36bfe03ac/alternative-reaction-condition-for-synthesizing-btk-inhibitor-biib091.png Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - Alternative Reaction Condition for Synthesizing BTK Inhibitor BIIB091 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ed9572c4-53e2-4a85-a0bc-0fdbfa076806/chemairs-proposed-alternative-reaction-conditions-for-friedel-crafts-acylation.png Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - ChemAIRS Proposed Alternative Reaction Conditions for Friedel-Crafts Acylation https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8316ac0e-b927-4795-b901-ff48294d71da/chemairs%27-proposed-potential-side-reaction-during-friedel-crafts-acylation-in-synthesizing-btk-inhibitor-biib091 Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - ChemAIRS' proposed Potential Side Reaction During Friedel-Crafts Acylation in synthesizing BTK Inhibitor BIIB091 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/73d583d1-ab5d-45ff-be4b-3a85182639c9/chemairs%27-proposed-alternative-reaction-conditions-for-intramolecular-pd-catalyzed-heck-reaction-in-synthesizing-btk-inhibitor-biib091 Blog - Leveraging ChemAIRS to Investigate Synthetic Strategies for Tetrahydrobenzoazepine Core of BTK Inhibitor BIIB091_EP13 - ChemAIRS' proposed Alternative Reaction Conditions for Intramolecular Pd-Catalyzed Heck Reaction in synthesizing BTK Inhibitor BIIB091 https://www.chemical.ai/blog/category/Precision+%26+Targeted+Medicine monthly 0.5 https://www.chemical.ai/blog/category/Synthetic+Methodology monthly 0.5 https://www.chemical.ai/blog/category/Metabolic+%26+Endocrine+Therapeutics monthly 0.5 https://www.chemical.ai/blog/category/Insecticides monthly 0.5 https://www.chemical.ai/blog/category/Retrosynthesis monthly 0.5 https://www.chemical.ai/blog/category/AI+in+Pharmaceuticals monthly 0.5 https://www.chemical.ai/blog/category/Computer-Aided+Synthesis+Planning+%28CASP%29 monthly 0.5 https://www.chemical.ai/blog/category/Artificial+Intelligence+in+Pharma monthly 0.5 https://www.chemical.ai/blog/category/Oncology+Research monthly 0.5 https://www.chemical.ai/blog/category/Pharmaceutical+Innovation monthly 0.5 https://www.chemical.ai/blog/category/AI+in+Chemistry monthly 0.5 https://www.chemical.ai/blog/category/Crop+Protection monthly 0.5 https://www.chemical.ai/blog/category/Oncology+%26+Disease+Applications monthly 0.5 https://www.chemical.ai/blog/category/AI+in+Drug+Discovery monthly 0.5 https://www.chemical.ai/blog/category/Clinical+Trials+%26+Therapeutics monthly 0.5 https://www.chemical.ai/blog/category/Artificial+Intelligence+in+Chemistry monthly 0.5 https://www.chemical.ai/blog/category/Drug+Discovery+%26+Development monthly 0.5 https://www.chemical.ai/blog/category/Therapeutic+Modalities+%26+Mechanisms monthly 0.5 https://www.chemical.ai/blog/category/Chemical+R%26D monthly 0.5 https://www.chemical.ai/blog/category/Materials+chemistry monthly 0.5 https://www.chemical.ai/blog/category/Medicinal+Chemistry monthly 0.5 https://www.chemical.ai/blog/category/Synthetic+%26+Medicinal+Chemistry monthly 0.5 https://www.chemical.ai/blog/category/Clinical+Trials+%26+Regulatory+Insights monthly 0.5 https://www.chemical.ai/blog/category/Agrochemistry monthly 0.5 https://www.chemical.ai/blog/category/Synthetic+Chemistry monthly 0.5 https://www.chemical.ai/blog/category/Digital+Chemistry+Tools monthly 0.5 https://www.chemical.ai/blog/category/OLED+materials monthly 0.5 https://www.chemical.ai/blog/category/Process+Optimization monthly 0.5 https://www.chemical.ai/blog/category/Drug+Development monthly 0.5 https://www.chemical.ai/blog/category/Oncology+Drug+Discovery monthly 0.5 https://www.chemical.ai/blog/category/Human%E2%80%93AI+Collaboration monthly 0.5 https://www.chemical.ai/blog/tag/TNF-%CE%B1+Inhibitors monthly 0.5 https://www.chemical.ai/blog/tag/Elironrasib+%28RMC-6291%29 monthly 0.5 https://www.chemical.ai/blog/tag/Retrosynthesis monthly 0.5 https://www.chemical.ai/blog/tag/Surzetoclax+synthesis monthly 0.5 https://www.chemical.ai/blog/tag/ChemAIRS+Retrosynthesis monthly 0.5 https://www.chemical.ai/blog/tag/AI+retrosynthesis monthly 0.5 https://www.chemical.ai/blog/tag/Oncology+Drug+Development monthly 0.5 https://www.chemical.ai/blog/tag/decarboxylative+cross-coupling monthly 0.5 https://www.chemical.ai/blog/tag/Synthetic+Route+Optimization monthly 0.5 https://www.chemical.ai/blog/tag/AI+in+Drug+Discovery monthly 0.5 https://www.chemical.ai/blog/tag/Sanofi monthly 0.5 https://www.chemical.ai/blog/tag/Precision+Medicine monthly 0.5 https://www.chemical.ai/blog/tag/Chemical+AI monthly 0.5 https://www.chemical.ai/blog/tag/PROTACs monthly 0.5 https://www.chemical.ai/blog/tag/bms-986458+synthesis monthly 0.5 https://www.chemical.ai/blog/tag/retrosynthesis monthly 0.5 https://www.chemical.ai/blog/tag/KRAS-G12C%28ON%29+Inhibitors monthly 0.5 https://www.chemical.ai/blog/tag/agrochemistry monthly 0.5 https://www.chemical.ai/blog/tag/Lymphoma+Therapy+Synthetic+Chemistry monthly 0.5 https://www.chemical.ai/blog/tag/Synthetic+Chemistry monthly 0.5 https://www.chemical.ai/blog/tag/RNA+Therapeutics monthly 0.5 https://www.chemical.ai/blog/tag/ChemAIRS monthly 0.5 https://www.chemical.ai/blog/tag/Orforglipron+%28LY3502970%29 monthly 0.5 https://www.chemical.ai/blog/tag/UCB+Pharma monthly 0.5 https://www.chemical.ai/blog/tag/ABBV-453 monthly 0.5 https://www.chemical.ai/blog/tag/Eli+Lilly monthly 0.5 https://www.chemical.ai/blog/tag/Bristol+Myers+Squibb monthly 0.5 https://www.chemical.ai/blog/tag/Revolution+Medicines monthly 0.5 https://www.chemical.ai/blog/tag/Drug+Discovery+and+Development monthly 0.5 https://www.chemical.ai/blog/tag/BCL-2+inhibitor monthly 0.5 https://www.chemical.ai/blog/tag/elironrasib+synthesis monthly 0.5 https://www.chemical.ai/blog/tag/GLP-1+Receptor+Agonists+%28GLP-1RAs%29 monthly 0.5 https://www.chemical.ai/blog/tag/Targeted+Protein+Degradation monthly 0.5 https://www.chemical.ai/blog/tag/Macrocyclic+Drug+Synthesis monthly 0.5 https://www.chemical.ai/blog/tag/radical+cross-coupling monthly 0.5 https://www.chemical.ai/blog/tag/insecticides monthly 0.5 https://www.chemical.ai/blog/tag/synthetic+chemistry monthly 0.5 https://www.chemical.ai/blog/tag/BCL6+Degrader monthly 0.5 https://www.chemical.ai/blog/tag/Retrosynthesis+Optimization monthly 0.5 https://www.chemical.ai/blog/tag/Diabetes+%26+Obesity+Therapeutics monthly 0.5 https://www.chemical.ai/blog/tag/AbbVie monthly 0.5 https://www.chemical.ai/blog/tag/Materials+chemistry monthly 0.5 https://www.chemical.ai/blog/tag/C%E2%80%93C+bond+formation monthly 0.5 https://www.chemical.ai/blog/tag/BMS-986458 monthly 0.5 https://www.chemical.ai/blog/tag/Balinatunfib monthly 0.5 https://www.chemical.ai/blog/tag/RCC+chemistry monthly 0.5 https://www.chemical.ai/blog/tag/Macrocyclic+Drugs monthly 0.5 https://www.chemical.ai/blog/tag/Balinatunfib+Synthesis monthly 0.5 https://www.chemical.ai/blog/tag/single-electron+chemistry monthly 0.5 https://www.chemical.ai/blog/tag/retrosynthetic+analysis monthly 0.5 https://www.chemical.ai/blog/tag/OLED+materials monthly 0.5 https://www.chemical.ai/blog/tag/Synthetic+pathways monthly 0.5 https://www.chemical.ai/blog/tag/Therapeutic+Modalities monthly 0.5 https://www.chemical.ai/news daily 0.75 2025-03-14 https://www.chemical.ai/news/partnership-emolecules monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741536802652-XC0ES4VQ5Q55PLWQ8O70/ChemicalAI-news-partnership-emolecules.jpg News - Chemical AI and eMolecules Enter a Strategic Partnership - eMolecules & Chemical.AI Accelerating Synthesis Planning and Simplify Compound Procurement, Together. https://www.chemical.ai/news/acceleration-consortium monthly 0.5 2025-05-16 https://www.chemical.ai/news/mcule-building-blocks-integration monthly 0.5 2025-05-16 https://www.chemical.ai/news/aragen-collaboration monthly 0.5 2025-05-16 https://www.chemical.ai/news/ntu-singapore-partnership monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741540439537-EE7COMZIZWCDBD7RJ02M/ChemicalAI-news-partnership-NTU-singapore.png News - Chemical.AI partners with NTU Singapore to advance automated and AI-powered research platform for nanomaterials - eMolecules & Chemical.AI Accelerating Synthesis Planning and Simplify Compound Procurement, Together. https://www.chemical.ai/news/carbonsilicon-ai-partnership monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6e082beb-94b3-4d09-9746-eb2a7b1c9e0b/ChemicalAI-news-partnership-CarbonSilicon-ai.png News - Chemical.AI and CarbonSilicon AI have Reached a Strategic Cooperation to Jointly Promote Drug Research and Development - eMolecules & Chemical.AI Accelerating Synthesis Planning and Simplify Compound Procurement, Together. https://www.chemical.ai/news/novalix-collaboration monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741542226711-TLU67LX9C79UTIZ7JX0B/ChemicalAI-news-partnership-NovAliX.png News - Chemical.AI and NovAliX Reached A Milestone in Collaboration https://www.chemical.ai/news/chemicalai-announced-a-partnership-with-pfizer-to-create-ai-driven-pharmaceuticals monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741542091333-S0J7SUH19T80I8YJ3SZ5/ChemicalAI-news-partnership-Pfizer.jpg News - Chemical.AI announced a partnership with Pfizer to create AI-driven pharmaceuticals https://www.chemical.ai/news/series-b-funding monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741542253151-KK2QH5FKICGUHXOCWTLD/ChemicalAI-news-14-million-series-B-funding.png News - Chemical.AI Announces nearly $14 million Series B funding https://www.chemical.ai/news/chemaxon-collab monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741542282223-RQ9MD41BBBQSWSM09QT8/ChemicalAI-news-partnership-Chemaxon.png News - Chemaxon and Chemical.AI Announce Collaboration in Scientific Informatics Software Integration https://www.chemical.ai/news/partnership-scilligence monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741542305380-BN4FG33NE9M4RZZSMX56/ChemicalAI-news-partnership-Scilligence.png News - Chemical.AI and Scilligence Launched their Strategic Cooperation to Co-develop ELN-based Data Integration https://www.chemical.ai/news/series-a-funding monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741542375396-2T5JQEH7HIQRBHPUWCV4/ChemicalAI-news-5-million-series-A-funding.png News - Chemical.AI Completed Series A Round of Funding of over 5 Million USD-Big Data and Artificial Intelligence Assist the Synthesis of Chemical Compounds https://www.chemical.ai/news/chemicalai-announced-a-partnership-with-pfizer-to-create-ai-driven-pharmaceuticals-2jl2f-mepwp-lyakg-m4tmd-623py-7gf78 monthly 0.5 2025-05-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/1741542404907-UJMFHEZBQWSVHLXAY2CS/ChemicalAI-news-partnership-NovAliX-drug-discovery.png News - NovAliX Partners with Chemical.AI to Develop Artificial Intelligence Toolkit for Drug Discovery https://www.chemical.ai/home daily 1.0 2025-11-13 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8adfee5b-0c5c-46d4-b0ab-1b222bb1fda1/yZlqh.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8adfee5b-0c5c-46d4-b0ab-1b222bb1fda1/yZlqh.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8adfee5b-0c5c-46d4-b0ab-1b222bb1fda1/yZlqh.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8adfee5b-0c5c-46d4-b0ab-1b222bb1fda1/yZlqh.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8adfee5b-0c5c-46d4-b0ab-1b222bb1fda1/yZlqh.png Home https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1618511387030-5LI1E5QMVTQ2RY9S00A4/20140228_Trade+151_0046+1.jpg Home https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1618511440608-5BVMHVN4WR2I9YQV1WWR/Aro+Ha_0010+1.jpg Home https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1618511467879-K5J9BYNACHJVDV3BNSFU/Aro+Ha_0387+1.jpg Home https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1618511743693-J3A8OYH6X8C7RXNU5K0J/20140301_Trade+151_0124+1.jpg Home https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1618497259178-6XJGK9GR6YAVBQL5L519/20140301_Trade-151_012-2.jpg Home https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1607694583486-2PQT0LQ193RL7MCB6DX4/20140228_Trade+151_0046.jpg Home https://images.squarespace-cdn.com/content/v1/5ec321c2af33de48734cc929/1607694644871-IC85FNH781UNZSZEGHDR/Aro+Ha_0428.jpg Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/644e0280-4e22-40c7-9d9a-9e2ee445149a/chemicalai-chemairs-synthesizability-assessment-sa-score-icon.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c6ba729e-f8e0-4940-bc69-8dedaa4ccd7f/chemicalai-partners-logos_pfizer.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/13d1f9b5-248c-40cc-962c-fd839508dced/chemicalai-partners-logos_roche.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7e4716a0-191d-4d1d-b4bf-b2a76cdf2276/chemicalai-partners-logos_l%27ore%CC%81al.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8d533def-b730-406a-9b73-3d088c140a58/chemicalai-partners-logos_wuxi-apptec.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a7d2c73a-f8a6-4b06-8e3d-081ed9819f45/chemicalai-partners-logos_pharmaron.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/22cd8165-fd32-453d-898a-83c4b437b8ce/chemicalai-partners-logos_frontier-medicines.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/abcc6f3e-1421-47b4-b9b3-f6685f593584/chemicalai-partners-logos_hengrui.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b4deb101-1754-4194-99f0-ba658def0e2c/chemicalai-partners-logos_aragen.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ec62a30f-b94c-4c12-a700-62b5ad655edd/chemicalai-partners-logos_hitgen.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/90262339-d75b-45e4-81a9-c8b2a0e4ea35/chemicalai-partners-logos_novalix.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/bc62002b-ad08-4aba-9399-bcd587fa40f7/chemicalai-partners-logos_agrofina.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/54252b31-9f2b-4777-b3ce-928736f71a94/chemicalai-partners-logos_mesentech.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/babad79e-05e8-4eaa-b911-e0e22cc5c621/chemical-ai-partners-logos_Genentech.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/45ad0a97-faff-4d95-821d-707c769417f8/chemical-ai-partners-logos_Paraza.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2db4355c-2e01-40f8-8496-7655d0d3dff8/chemical-ai-partners-logos_Molport.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/69d9bfac-bc17-457d-bd2b-489967220f96/chemical-ai-partners-logos_Enamine.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f3b006f6-ecf0-4794-960f-89698bb6d206/chemical-ai-partners-logos_bioduro-sundia.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6eaf722a-a74e-495c-a69c-c58bd6e51e21/chemical-ai-partners-logos_university-of-toronto.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/85effdcb-171d-4aaa-8fce-b11b97c96e6c/chemical-ai-partners-logos_superluminal-medicines.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c84f95a6-eff1-480e-9063-71ec51b891ed/20250917-085707.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/25b3a1d1-54e2-4ac2-9df6-cf894e4c373d/20250917-085714.png Home https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/75f507fc-3e8a-4297-b25d-d922d2432404/smarter-synthesis-starts-here-02.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/70698bc0-4684-42e1-8224-c03a3bde4c40/chemairs_-monitor-light-interface-01.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8fc842da-1d3f-4544-8bef-463d1263725b/chemairs_-monitor-light-interface-02.png https://www.chemical.ai/contact daily 0.75 2025-11-13 https://www.chemical.ai/chemairs daily 0.75 2025-03-18 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/19a0459b-92df-44b5-91f9-94845ab73b3b/chemairs-impurity-prediction-tool.png ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3ccfdede-e6e3-4d1c-aa1c-044a12f89364/chemairs-condition-optimization.png ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/5d9e9feb-38f4-4f97-ad76-3bf7d81b948d/chemairs-forward-synthesis.png ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4df06af4-ce17-4c84-9e31-5a725b816d68/chemairs-secure-eln-icon.png ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/cd254fa6-f0c5-4919-aaf1-dc5751fab89e/chemairs-real-time-cost-icon.png ChemAIRS https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f0a1a6d1-13ce-4a56-999b-ed3d4b19637e/chemairs-type-01.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/3c3c4c22-018a-414e-a2ca-025e167e33e5/chemicalai-chemairs-retrosynthesis-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e885388e-12c1-4e31-8fe0-8eafadca9640/chemicalai-chemairs-process-chemistry-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/644e0280-4e22-40c7-9d9a-9e2ee445149a/chemicalai-chemairs-synthesizability-assessment-sa-score-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/35af0427-6547-460b-8036-a7a66c99fba2/chemairs_-monitor-dark-interface-01.png https://www.chemical.ai/about daily 0.75 2025-09-17 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/13d1f9b5-248c-40cc-962c-fd839508dced/chemicalai-partners-logos_roche.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c6ba729e-f8e0-4940-bc69-8dedaa4ccd7f/chemicalai-partners-logos_pfizer.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/7e4716a0-191d-4d1d-b4bf-b2a76cdf2276/chemicalai-partners-logos_l%27ore%CC%81al.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8d533def-b730-406a-9b73-3d088c140a58/chemicalai-partners-logos_wuxi-apptec.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a7d2c73a-f8a6-4b06-8e3d-081ed9819f45/chemicalai-partners-logos_pharmaron.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/22cd8165-fd32-453d-898a-83c4b437b8ce/chemicalai-partners-logos_frontier-medicines.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/abcc6f3e-1421-47b4-b9b3-f6685f593584/chemicalai-partners-logos_hengrui.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b4deb101-1754-4194-99f0-ba658def0e2c/chemicalai-partners-logos_aragen.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ec62a30f-b94c-4c12-a700-62b5ad655edd/chemicalai-partners-logos_hitgen.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/90262339-d75b-45e4-81a9-c8b2a0e4ea35/chemicalai-partners-logos_novalix.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/bc62002b-ad08-4aba-9399-bcd587fa40f7/chemicalai-partners-logos_agrofina.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/54252b31-9f2b-4777-b3ce-928736f71a94/chemicalai-partners-logos_mesentech.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/babad79e-05e8-4eaa-b911-e0e22cc5c621/chemical-ai-partners-logos_Genentech.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/45ad0a97-faff-4d95-821d-707c769417f8/chemical-ai-partners-logos_Paraza.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/69d9bfac-bc17-457d-bd2b-489967220f96/chemical-ai-partners-logos_Enamine.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f3b006f6-ecf0-4794-960f-89698bb6d206/chemical-ai-partners-logos_bioduro-sundia.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/85effdcb-171d-4aaa-8fce-b11b97c96e6c/chemical-ai-partners-logos_superluminal-medicines.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/fb657cf1-06ce-4a17-9c26-90d770abbbe8/20250829-125726.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/04d517c9-8756-446e-810f-9e8112f1a320/20250829-125705.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/78e32006-59dc-4050-9231-bae4ca0b71f9/20250829-125715.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f5bc106e-bcb0-46f4-9883-9da93d7030d4/20250917-085621.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/37b56b5c-c8b0-4682-b909-217530701acb/20250917-085634.png About https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/70698bc0-4684-42e1-8224-c03a3bde4c40/chemairs_-monitor-light-interface-01.png https://www.chemical.ai/condition-optimization daily 0.75 2025-03-18 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/995e352d-d7f7-41cb-b889-aa67baa2b6f2/chemairs-features-condition-optimization-hero-01.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/d86cf887-9f9a-496c-983d-2c103a5b47f3/chemairs-feature-condition-optimization-02.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6e62c083-16d3-43c0-acc2-6849c76da090/chemairs-feature-condition-optimization-03.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4ea06350-c2ea-457a-93db-440d5b3014aa/chemairs-screen_-condition-optimize-export-data.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8fc842da-1d3f-4544-8bef-463d1263725b/chemairs_-monitor-light-interface-02.png https://www.chemical.ai/retrosynthesis daily 0.75 2025-03-18 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/5b225c85-3bf8-4dac-ab92-6da99782957b/chemairs-features-retrosynthesis-icon-color.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/6fa4119b-01f1-4566-8cb1-f26e6f7f23b5/retrosynthesis-route-design-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/84f5c1cb-138c-4d2a-94bf-baad98b9d0ce/retrosynthesis-speed-up-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/001a6b5a-5249-4adb-a231-6fd301dee9de/retrosynthesis-building-block-data-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e300f104-651c-4115-9f73-97e7f8172eae/retrosynthesis-eln-data-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/312c142e-f28e-4bc3-9bda-0d0a472931c5/retrosynthesis-local-deployment-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/5fee2827-cbe1-4bb8-b767-d09fd28869cb/chemairs_-monitor-dark-interface-02.png https://www.chemical.ai/synthesizability daily 0.75 2025-03-18 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/541be6db-35f3-4ee8-a18a-34211627eacf/chemairs-SA-score-icon-01.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f3c96519-54bf-4991-865c-3cb320b917fd/chemairs-sa-score-icon_reaction-logic.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/e70442e2-e944-4c59-aad6-dbe427ba9a4a/chemairs-sa-score-icon_building-blocks.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/64c690d9-cb4c-4608-9e51-10e53fb9a48c/chemairs-sa-score-icon_cost.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c87c4510-15df-4ad5-94d2-aee8a6a533e5/airs-product07.jpg https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/677fb174-c67b-4347-9263-e655bbd2d644/chemairs-merck-synthesis-study-1346-molecules.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/35af0427-6547-460b-8036-a7a66c99fba2/chemairs_-monitor-dark-interface-01.png https://www.chemical.ai/impurity-prediction daily 0.75 2025-03-16 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/9d363dd6-143d-47f4-8842-520ac8d97b6b/chemairs-features-impurity-prediction-icon-01.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4394afba-59d9-4ebe-9ab7-8021aa1b87ad/Impurity-prediction.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f5aec09a-b7b8-4762-9436-8ab8b91dab2d/chemairs-impurity-prediction-orpd.png https://www.chemical.ai/copyright daily 0.75 2025-03-10 https://www.chemical.ai/process-chemistry daily 0.75 2025-03-18 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/19334bbf-0281-4028-a510-7c80acd41851/chemairs-features-process-chemistry-icon.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/0bf956e9-c3d2-45b1-97e2-38e2e265dfa0/chemairs-process-chemistry_smarter-route.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/8eb95d1a-c08f-4eba-8681-d81bc04ba549/chemairs-process-chemistry_optimize-condition.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/61ae4da7-d0b3-4fbb-96f5-52a6d8945fbc/chemairs-process-chemistry_alternative-reagents.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4b12bfce-e03b-4dc3-a024-2d561e95fed6/chemairs-process-chemistry_scale-up.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/b4deb101-1754-4194-99f0-ba658def0e2c/chemicalai-partners-logos_aragen.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/c6ba729e-f8e0-4940-bc69-8dedaa4ccd7f/chemicalai-partners-logos_pfizer.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/abcc6f3e-1421-47b4-b9b3-f6685f593584/chemicalai-partners-logos_hengrui.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/35af0427-6547-460b-8036-a7a66c99fba2/chemairs_-monitor-dark-interface-01.png https://www.chemical.ai/forward-synthesis daily 0.75 2025-03-12 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f85d202a-574b-4a47-afdb-3b1166a0b5b8/chemairs-forward-synthesis-core-analysis.png Forward Synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2c9c56da-4ad5-4bc7-ba52-c9dc251edb8e/chemairs-forward-synthesis-core-stability.png Forward Synthesis https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f4c3dd92-7c20-4ed5-9355-a7e911988624/chemairs-forward-synthesis-icon.png https://www.chemical.ai/404 daily 0.75 2025-03-07 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/a0250ccd-d6ab-4e41-9171-0e4bb33875f6/chemical-ai-404-search.png https://www.chemical.ai/privacy-policy daily 0.75 2025-03-13 https://www.chemical.ai/cookie-notice daily 0.75 2025-03-09 https://www.chemical.ai/impurities-case-studies daily 0.75 2025-03-20 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/68fd245c-4a1a-4505-9195-9b1fccffdf21/Screenshot+2025-03-20+112541.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/d50c4e0d-e7c8-4067-888f-3ba0c7ee193d/Screenshot+2025-03-20+114102.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/ced8a4bd-de20-461f-9c24-aa0968684966/Screenshot+2025-03-20+114247.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/bc31ddd3-cb89-43fd-b5ae-1172ae9c65ce/Screenshot+2025-03-20+114442.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/9101824c-0319-47d6-b3bc-48bb1c28ac18/Screenshot+2025-03-20+114737.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/9a07faf9-e7d8-4b72-900f-8d348d8baff3/Screenshot+2025-03-20+114813.png https://www.chemical.ai/bayesian-optimization daily 0.75 2026-01-14 https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/f85d202a-574b-4a47-afdb-3b1166a0b5b8/chemairs-forward-synthesis-core-analysis.png Bayesian Optimization https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/2c9c56da-4ad5-4bc7-ba52-c9dc251edb8e/chemairs-forward-synthesis-core-stability.png Bayesian Optimization https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/995e352d-d7f7-41cb-b889-aa67baa2b6f2/chemairs-features-condition-optimization-hero-01.png https://images.squarespace-cdn.com/content/v1/6791175e69de217943348124/4394afba-59d9-4ebe-9ab7-8021aa1b87ad/Impurity-prediction.png